Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Pathological Complete Response in TNBC
Immunotherapy Combined With Chemotherapy Shows Higher Response Rates in TNBC
Combining immune checkpoint inhibitors with chemotherapy significantly improves pathological complete response rates in patients with triple…
Adding immunotherapy to chemotherapy may improve response rates for patients with early-stage or high-risk triple-negative breast cancer.
High-throughput omics approaches identify biomarkers for myocarditis, pneumonitis, and colitis in ICI patients
Mapping biomarkers to track side effects from cancer treatments
This scoping review of 86 studies maps omics-based biomarkers for immune-related adverse events (irAEs) including myocarditis, pneumonitis, …
New research maps complex biological data to help identify and monitor serious side effects caused by immune checkpoint inhibitors.
Multifaceted mechanisms including replication fork stabilization and epigenetic reprogramming drive PARP inhibitor resistance in ovarian cancer
New Strategies May Help Overcome Ovarian Cancer Treatment Resistance
This narrative review explores the mechanisms of resistance to PARP inhibitors in patients with advanced epithelial ovarian cancer. The auth…
Researchers are identifying specific biological mechanisms that cause ovarian cancer to resist PARP inhibitors, opening doors for new treatm…
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Nurse-coordinated monitoring of biomarkers and symptoms supports clinical assessment for immune checkpoint inhibitor safety
Nurse-Led Monitoring Helps Manage Side Effects of Cancer Treatment
This narrative review explores the role of nurse-coordinated biomarker and symptom monitoring in patients receiving immune checkpoint inhibi…
Nurse-coordinated monitoring of symptoms and biomarkers helps manage side effects from immune checkpoint inhibitors in cancer patients.
Gut microbiome composition correlates with clinical outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors
Gut bacteria may influence how liver cancer patients respond to treatment
This meta-analysis of 13 papers examines the relationship between gut microbiota and clinical outcomes in patients with intermediate-to-adva…
Specific types of gut bacteria are linked to how well liver cancer patients respond to immune-based therapies.
Impact of RAS and BRAF Mutation Status on Immune Checkpoint Inhibitor Efficacy
Understanding How Genetic Markers Affect Treatment Success in Colorectal Cancer
Meta-analysis reveals that while ORR remains consistent across subgroups, BRAF mutations significantly correlate with poorer survival outcom…
New data shows that specific genetic markers can change how well certain drugs work for patients with advanced colorectal cancer.
Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
Adding Chemotherapy to Immune Therapy for Lung Cancer Shows Mixed Results
A meta-analysis of 3,252 patients reveals that adding chemotherapy to ICI monotherapy does not provide a consistent survival advantage.
New analysis suggests that adding chemotherapy to immunotherapy for certain lung cancers may not provide a consistent survival benefit over …
Perioperative and postoperative immunotherapy timing determines clinical outcomes in locally advanced head and neck squamous cell carcinoma
Timing of immunotherapy affects outcomes for head and neck cancer
This narrative review examines the impact of immunotherapy sequencing on patients with locally advanced head and neck squamous cell carcinom…
The timing of immunotherapy treatment significantly changes how well it controls local and distant spread in head and neck cancer.
Statin use is associated with improved overall survival and progression-free survival in lung cancer
Statin use linked to better survival in lung cancer patients
This meta-analysis of 5,156 patients found that statin use was associated with significantly improved overall survival (HR = 0.76) and progr…
New data suggests that patients taking statins may live longer and stay cancer-free longer while undergoing specific lung cancer treatments.
Age and sex drive distinct immune microenvironment and evasion mechanisms in cancer patients
Age and sex influence how cancer drugs work in patients
This systematic review synthesizes how age and sex influence the anti-tumor immune microenvironment and immune evasion mechanisms. The autho…
New research shows that a patient's age and sex change how their immune system fights cancer and responds to treatment.
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…